The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

/PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious diseases,...

Related Keywords

Chicago ,Illinois ,United States ,Netherlands ,London ,City Of ,United Kingdom ,Oegstgeest ,Zuid Holland ,Anthony Kong ,Drug Administration ,King College ,Principal Investigator ,Human Papilloma Virus ,Medical Oncologist ,Chief Medical Officer ,Disease Control Rate ,Fast Track ,Isa Pharmaceuticalsbv ,